Bratherton D G, Brown C H, Buchanan R, Hall V, Kingsley Pillers E M, Wheeler T K, Williams C J
Br J Cancer. 1984 Aug;50(2):199-205. doi: 10.1038/bjc.1984.163.
In a comparative double-blind trial involving 263 postmenopausal women with advanced breast cancer treated with tamoxifen, the mean objective tumour response rate and duration was 32% and 15 months respectively. No significant difference was found in clinical response and adverse effects between those randomised to 10 mg and those to 20 mg twice daily. Although the mean serum concentration of tamoxifen in the 20 mg bd group was significantly higher no correlation between serum level and clinical benefit was demonstrated.
在一项涉及263名接受他莫昔芬治疗的绝经后晚期乳腺癌女性的双盲对照试验中，客观肿瘤缓解率均值和缓解持续时间分别为32%和15个月。随机分为每日两次服用10毫克组和20毫克组的患者，在临床反应和不良反应方面未发现显著差异。虽然每日两次服用20毫克组的他莫昔芬血清浓度均值显著更高，但未证明血清水平与临床获益之间存在相关性。
